Table 2: Efficiency of different mitogens and karyotypes in 18 patients with SMZL.

PatientAgeSample (*)Score (**)  Karyotype
TPALPSODN + IL2
Quality Proliferation Efficiency Quality Proliferation Efficiency Quality Proliferation Efficiency

170Pb (21.9)33N32N33N46, XY [20]
278BM (38%)23N23A33A47, XX, +12 [2]/46,XX [18]
377Pb (7.28)01F13A33A47, XY, add(5)(p15),+22 [15]/47, XY, add (5)(p15), del (7)(q22),
i(8)(p10), +del (14)(q24) [5]
475BM (35%)33N34A32ANear tetraploid: 91, XXY, idic (1)(p11), del (11)(q21),
add(14)(q32), +mar1, +mar2 [3]/46, XY [17]
576Pb (8.63)01F01F23A46, XY, der (3)(p26), del (7)(q32), del (13)(q22) [4]/46, XY [21]
669Pb (34.8)01F33N33N46, XY [20]
755Pb (16.1)33N32A33A46, XY, t(3;13)(q21;q13), del (11)(q12) [13]/46, XY [7]
884Pb (20)01F33A43A46, XX, -9, t(14;19)(q32;q13), +add (14)(q32) [19]/46, XX [1]
976Pb (4.5)33A33A44A47, XY, +12 [15]/46, XY [5]
1063Pb (NA)24N23N24N46, XY [20]
1186Pb (6.1)33A12A33A46,XX,del(14) (q22) [16]/46,XX [5]
1276Spleen01F01F23N46, XX [20]
1375Pb (23.1)33N12N34A48, XY, +12, +15 [5]/46, XY [15]
1483BM (30%)23N23N24A46, XY, del (3)(p13) [3]/46, XY [17]
1585Pb (4.2)01F33A33A47, XY, +12, del (14)(q24) [12]/46, XY [8]
1672Pb (2.9)01F01F43A46, XY, dup (1)(q21q32), del (7)(q32), del (13)(q14q22) [2]/47, XY, del (7)(q32), der (12) t(3;12)(p11;p11),
del (13)(q14q22), +mar1 +mar2 [1]/46, XY [17]
1756Pb (4.9)33A34A33A46, XY, del (7)(q32) [8]/46, XY [12]
1882Pb (7.1)32N01F33A47, XX, +3 [4]/46, XX [16]

*Absolute lymphocyte count × 109/L at the time of cytogenetic investigation, or % BM infiltration, as appropriate. NA: not available.
**See materials and methods for details; A: abnormal, N: normal, and F: failure.